The WHO’s first global guidance prioritises supervised lifestyle and behavioural support for younger children, while restricting medicines and surgery to carefully selected older adolescents.
The World Health Organisation has issued its first global guidance on obesity in children and adolescents, drawing a firm line against weight-loss medicines, surgery and medical devices for children under 10 and setting a far narrower role for drugs in older teenagers. In a statement released on 7 October, the agency said treatment for younger children should centre on supervised dietary, physical activity and behaviour-changing support, rather than medical intervention. Medical Daily and WHO both said the advice is aimed at policymakers, programme managers and health workers responsible for delivering care. According to WHO, the aim is integrated, people-centred treatment that weighs not only clinical benefit but also feasibility, cost and family preferences.
The guidance is built around a staged model of care. WHO’s publication says structured interventions can be delivered individually or as part of a multimodal programme, while digital health tools are recommended only conditionally and with a parent or caregiver involved. For children under 10, WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices. For adolescents aged 10 to 19, approved medicines may be considered only after a supervised lifestyle programme has failed to deliver the desired results, and surgery is reserved for severe obesity under strict conditions. The agency says the recommendations are based on systematic evidence reviews.
WHO framed the issue as both a medical and social challenge, warning that anxiety, depression, low self-esteem and emotional dysregulation can all feed unhealthy eating patterns and inactivity. “The foundation of obesity care for children and adolescents is not medicine or surgery,” said Dr Luz María De Regil, who heads WHO’s nutrition and food safety department. The agency also urged health services to address obesity and mental health together, rather than as separate problems. That approach reflects the organisation’s view of obesity as a chronic, relapsing disease that can be managed, but not solved, by treatment alone.
The scale of the problem explains the urgency. WHO said 170 million people aged 5 to 19 were living with obesity in 2024, including 70 million children aged 5 to 9 and 100 million adolescents aged 10 to 19. It added that prevalence in that age group has risen fourfold since 1990, from 2% to 8%. Even so, the agency acknowledged that treatment access remains uncertain, because the guidance assumes supervised programmes are available in the first place. WHO said wider action is still needed on food regulation, taxes, education, transport, urban design and social protection if healthy diets and physical activity are to become easier to access and afford.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
